Pfizer Neuroscience Update:

The Vision Becomes Reality

Pfizer Has Opportunity to Gain #1 Position in Worldwide Neuroscience Sales

THE PFIZER NEUROSCIENCE VISION Through innovative research, strategic partnerships, and an unsurpassed commitment to disease education, Pfizer Neuroscience is dedicated to being the leading provider of neurologic and psychiatric medicines that make a meaningful difference in the lives of patients and their families around the world

Many Local Markets Are Actively Building The Neuroscience Vision

A significant opportunity exists to capitalize on disease markets A strong future begins by maximizing our current portfolio

Performance Goals Delivered & Acknowledged Build Neuroscience Franchise by Leveraging Your Local Strengths & Opportunities Capitalize on Opportunities with Programs & Materials
Materials Developed in Response to Your Requests in 2001
Leverage the Franchise Leveraging growth through capitalizing on product range

Leverage Unmatched Neuroscience Portfolio

Pfizer Depression Eli Lilly GSK J&J Novartis

Recognize and Reward Superior Neuroscience Market Performance in the Local Marketplace Award for Substantial Growth in Marketplace Countries Where Pfizer Neuroscience Sales Rank #1 in Local Neuroscience Market

Cerebyx

Neuroscience Leadership Internal Communication Materials Roadmap Film Slide Kit Posters/Banners Colleague Card

OR
Local Pfizer Neuroscience Growth Exceeds the Local Neuroscience Market Growth by 15% OR Pfizer Ranks #2 in Local Neuroscience Sales and Is Growing at a Rate 2 Times the Local Market Leader

Epilepsy

Migraine

Schizophrenia

Develop Product Performance Product-based strategy to develop and sustain competitive advantage set

Develop Market Franchise Extending product range and/or meeting secondary customer needs

Neuroscience Field Aids for OL Film Slide Kit Brochure

AD

Effective implementation of the strategy: doing the right thing right; adding value to customers

Performance Leaders to Date

Additional Initiatives Being Evaluated for 2002-2003 Website Enhancements

(fosphenytoin sodium injection)

(sertraline HCl)

The broadest portfolio in the category worldwide Significantly greater potential based on: New product launches New indications Solid clinical data

Key Strategies For Leveraging The Vision Develop strong relationships with key opinion leaders Integrate The Vision into the operating plan Optimize communication opportunities

Neuroscience Day Templates and Information Journal Ad Convention Exhibit Pfizer Neuroscience Articles

Continue strong performance Work toward top leadership position

Patient Information Program RELPAX

The Netherlands
Objectives Next steps: Market Research
To increase patient loyalty to RELPAX as a step 2: Qualitative significant number of patients drop out Method: 12 group discussions among: treatment within a short period of time. 2 x 6 loyalists; To differentiate RELPAX from the competitors: 2 x 6 switchers; RELPAX is offering added value in order to 2 x 6 lapsers; optimize migraine treatment. 2 x 6 GPs; 2 x 6 neurologists; Patient Loyalty Definition 2 x 6 pharmacists. Loyal: no change in Rx products. Results (expected): April 2002. Switch: last 2 years minimal 2 Rx products. Lapsed: Rx in the last 3 years, but not during Next steps: Compose Task Force last year. Task Force Patient Information Program. Objective: Advisory Board to support Background development & implementation of Patient Extensive patient information program has been Information Program. developed by Pfizer HQ; basic materials have Members: GPs, Neurologists, Pharmacists & been available since Q4 2001. Migraine Patient Association. The Netherlands serve as pilot implementation 1st meeting planned in April 2002. country for Pfizer HQ. No Dutch market research available giving Next steps: Legal Check insight in loyalty/disloyalty and the drivers for Branded direct to consumer communication is it. forbidden. Physicians are not allowed to distribute Next steps: Market Research premium items (such as t-shirts). step 1: Quantitative Exploration of possibilities within Dutch Patient Flow Mapping by NIPO legislation (results: March 2002). Objective: screening of 500 migraine patients according to IHS criteria (Rx users & non-Rx Program Implementation users). Implementation in primary care. Method: by telephone. Launch: (expected) September 2002. Results (expected): March 2002. Link with observational clinical trial is considered. Next steps: Market Research Objective: enrollment of 2,500 patients step 2: Qualitative (250 GPs x 10 patients). Objectives: 1) To get a deeper insight in the motives and Co-operation Pfizer HQ behaviour of the patients with reference to The Netherlands Rx & to get insight in the willingness of HQ physicians to co-operate with a patient Development of materials/ideas. information program. Funding. 2) To get insight into the comprehension & The Netherlands acceptance of the developed patient Pilot-implementation of Patient Information information materials. Program.

Lessons Learned Rhythms

Win-win situation prior condition. ROI difficult to achieve. Resistance to linked product-program. Motivation Field Force: Key Success Factor. Positive attitude physicians (we need to offer them more than patient benefits).

LEARNING OBJECTIVES After taking part in this activity, the participant should be able to: Recognize the impact of a traumatic event on individuals and the community Differentiate between those who are suffering normal acute stress reactions and those who may be suffering from posttraumatic pathologies Describe the signs and symptoms of posttraumatic pathologies Explain behavioral, psychological, and pharmacologic management strategies for patients who experience traumatic events Recognize community support resources for individuals suffering from a traumatic event TARGET AUDIENCE This activity is designed for primary care physicians, psychiatrists, psychologists, and other mental healthcare professionals. ACCREDITATION The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity. CREDIT DESIGNATION The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 1 hour in Category 1 credit toward the AMA Physicians Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. POLICY ON FACULTY AND SPONSOR DISCLOSURE It is the policy of The Johns Hopkins University School of Medicine that the faculty and sponsor disclose real or apparent conflict of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Detailed disclosure will be made in the course handout materials. STATEMENT OF NEED The need for this program results from the current potential for increased numbers of individuals seeking help from their physicians after exposure to the recent, and possibly ongoing, terrorist events and subsequent war. Physicians may see increased numbers of patients exhibiting stress-related behaviors.

You are invited to attend

Sponsored by

The Johns Hopkins University School of Medicine

This activity is supported by an unrestricted educational grant from Pfizer Inc.

This educational activity is supported by an unrestricted educational grant from Pfizer Inc. If you wish to have your fax number removed from the AMA's Physician Fax Database call 1-800-262-3211.

Management of Patients With Depression & Anxiety

Issues in Managed Care

ATTITUDES ARE CHANGING

MEDIA COVERAGE European premiere and further screenings National press and television coverage Invited guests including many key opinion leaders Reviews by doctors in medical press Special supplement in national GP journal Pulse Press pack produced in association with the Alzheimers Society Commissioned article from key opinion leader, Dr Wilkinson REGIONAL SCREENINGS Introduced by local key opinion leaders Over 1000 selected delegates to date Further screenings arranged SPECIAL SCREENINGS Dementias 2000 meeting Royal College of Physicians Changing Minds Campaign Alzheimers Society Regional Fund Raisers

Supporting awareness in Alzheimers

Ziprasidone Bipolar Disorder Advisory Board

Pharmacologic Management of Agitation

emergency inpatient

outpatient

discharge

Advances Toward a New Era

The Case-Study Continuum Teleconference Workbook

Date of release: July 18, 2003 Expiration date: July 18, 2005 Sponsored by

The Johns Hopkins University School of Medicine

University of Tennessee College of Pharmacy

Supported by an unrestricted educational grant from Pfizer Inc.

New Strategies in the Emergency Management

N EATBHDEOF ITAFGACUTE CPSYCHOSIS

P N

TARGET AUDIENCE
Medical directors and pharmacy directors. There are no prerequisites to participate in this activity.

CREDIT DESIGNATION
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Johns Hopkins University School of Medicine and the Illinois Pharmacists Association. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physicians Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. This program is approved for 2 contact hours (.20 CEUs) by the Illinois Pharmacists Association as a provider of continuing pharmaceutical education. Date of release: December 31, 2003 Expiration date: December 31, 2004 Estimated time to complete activity: 2 hours
Illinois Pharmacists Association 2003, All rights reserved, The Johns Hopkins University School of Medicine and produced by Innovative Medical Education, Paramus, NJ
This program is supported by an unrestricted education grant from Pfizer Inc.

HEALTH AND ECONOMIC

CONSEQUENCES IN

SCHIZOPHRENIA
Sponsored by

Learning Objectives Part A: Advances Toward a New Era

Upon conclusion of this program, participants should be able to: Understand behavioral emergencies and preferred initial interventions as defined by the Expert Consensus Guidelines for the Treatment of Behavioral Emergencies Provide short-term and long-term goals in the treatment of agitation Review the benefits and limitations of current treatments for agitated patients, including the use of intramuscular (IM) benzodiazepines and IM typical antipsychotic agents Compare and evaluate efficacy, tolerability, and safety data for the new IM atypical antipsychotic agent Address the transition to oral therapy, including the role of oral atypical antipsychotic agents in the medium-term to long-term management of the agitated patient

The continuing pharmacy education portion of this program is cosponsored with the University of Tennessee College of Pharmacy and is approved for 2 hours of credit (0.2 CEUs)1 hour for Part A and 1 hour for Part B. The University of Tennessee College of Pharmacy is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education. A statement of continuing education hours will be mailed within 3 weeks of completion to those pharmacists participating in the program who complete the program evaluation instrument and successfully complete the self-assessment instrument at the conclusion of the program. (Term of approval is 3 years from release date of September 2003.) ACPE Program Number: Part A064-999-03-247-H01, Part B064-999-03-248-H01 This educational activity is supported by an unrestricted educational grant from Pfizer Inc. Date of release: September 1, 2003 Expiration date: September 1, 2005

System Requirements
Windows Pentium II or higher recommended Windows 98SE, ME, NT4, 2000, XP 64 MB or more of installed RAM Macintosh Power Macintosh Power PC processor (G3 or higher recommended) Mac OS9 to Mac OSX 10.x 64 MB or more of installed RAM

Statement of Need
The development of this program results from the need to provide information on new strategies for the management of the patient who presents with acute agitation. The patient with agitation is managed in the emergency room and then followed through the continuum of care to ensure the quality of patient care from the emergency room to the inpatient unit to the community setting.

Part B: The Case-Study Continuum

Upon conclusion of this program, participants should be able to: Provide a global view of the continuum of care of patients presenting with acute agitation, from the emergency room to the community Recognize presentations of acute agitation with multiple origins Evaluate effective treatment regimens for acute agitation Determine the best course of action for patients following initial intervention in the emergency room Develop treatment plans for patients admitted to the inpatient unit Design strategies for discharge and maintenance therapy Understand how to assist with integration into the community setting for improved outcomes

Target Audience
This activity is designed for psychiatrists, emergency medicine physicians, inpatient healthcare professionals, community mental healthcare professionals, nurses, nurse practitioners, pharmacists, and other allied healthcare professionals. There are no prerequisites for participation.

Hardware Requirements
10x CD-ROM drive 800 x 600 graphics display 16 bit color graphics board 16 bit sound board with speakers

To Apply for Credit for This Activity

Listen to the CD and view the accompanying slides Complete the posttest and submit online (at www.hopkins-pma.com) or mail or fax the form included on this CD as directed.

Operating Instructions
1. Insert the CD into the CD-ROM drive. The program will automatically begin. 2. If the program does not begin locate your CD-ROM drive and doubleclick on the icon named AgitManag. 3. Instructions for completing and submitting the posttest are provided on the PDF file on this CD.
Copyright 2003 The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing. Produced by Innovative Medical Education, Paramus, NJ

Full Disclosure Policy Affecting Continuing Education Activities

As sponsors accredited by the ACCME and the ANCC, it is the policy of The Johns Hopkins University School of Medicine, The Institute for Johns Hopkins Nursing, the American College of Emergency Physicians, and the University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.

Accreditation Statements
The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME activity. The Institute for Johns Hopkins Nursing is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Centers Commission on Accreditation. The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 category 1 credits toward the AMA Physicians Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity. The Institute for Johns Hopkins Nursing designates this activity for a maximum 2 contact hours. Claim only those contact hours actually spent in the activity. Approved by the American College of Emergency Physicians for 2 hours of ACEP category 1 credit. Estimated time to complete this activity: 2 hours.

Notice of Unlabeled/Unapproved Uses

NOTICE: In accordance with the ACCME and ANCC Standards for Commercial Support, the audience is advised that one or more presentations in this continuing medical education activity may contain reference(s) to unlabeled or unapproved uses of drugs or devices.

Disclaimer Statement
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of The Johns Hopkins University School of Medicine and The Institute for Johns Hopkins Nursing names implies review of educational format design and approach. Please note: the people described in the cases included in this program are fictional.

Editorial Board Faculty

David G. Daniel, MD (chair) Clinical Professor of Psychiatry and Behavioral Science The George Washington University School of Medicine and Health Sciences Washington, DC Director of Clinical Trials Stanley Medical Research Institute Bethesda, Maryland Paul Rivkin, MD (chair) Assistant Professor Division of Psychiatric Neuroimaging Department of Psychiatry The Johns Hopkins University School of Medicine Baltimore, Maryland Michael Allen, MD Director of Inpatient Psychiatry Colorado Psychiatric Health Denver, Colorado Matthew A. Fuller, PharmD, BCPS, BCPP Associate Clinical Professor of Psychiatry Clinical Instructor of Psychology Case Western Reserve University Cleveland, Ohio Clinical Pharmacy Specialist, Psychiatry Pharmacy Services Louis Stokes Veterans Affairs Medical Center Brecksville, Ohio Linda D. Gerson, PhD, RN Licensed Nurse Psychotherapist Board Certified Advanced Practice Psychiatric Mental Health Nurse The Johns Hopkins University School of Nursing Baltimore, Maryland Douglas H. Hughes, MD Associate Professor Department of Psychiatry Boston University School of Medicine Boston, Massachusetts Alan J. Mendelowitz, MD Assistant Professor of Psychiatry Albert Einstein College of Medicine Bronx, New York Director of Inpatient Research/ Residency Training Unit Hillside Hospital Glen Oaks, New York Long Island Jewish Medical Center New Hyde Park, New York Dan L. Zimbroff, MD Medical Director Pacific Clinical Research Medical Group Upland, California

Sponsored by

The Johns Hopkins University School of Medicine University of Tennessee College of Pharmacy
Supported by an unrestricted educational grant from Pfizer Inc.

Depression &Anxiety
Issues in Managed Care

Management of the Patient With

Pediatric Major Depressive Disorder Advisory Board

SOCIAL ANXIETY DISORDER Advisory

Board

226_0110_YWCA_Invite

5/3/02

9:45 AM

Page 1

YWCA of the U.S.A.

presents

TM

TM

Trauma shatters assumptions; it destroys the wall of safety and invulnerability that we use to shield ourselves from harsh realities witnessing trauma produces a similar effect on the bystander. Sandra Bloom, Creating Sanctuary

PSYCHIATRY RESIDENT
2 0 0 2 A W A R D P R O G R A M

Multinational Primary Care Summit on

DEPRESSION AND ANXIETY DISORDERS